⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23538657 | 0.97 | — | — | |
| SCHEMBL7091816 | 0.92 | — | — | |
| SCHEMBL7094176 | 0.77 | — | — | |
| SCHEMBL708463 | 0.72 | — | — | |
| SCHEMBL26132841 | 0.72 | — | — | |
| SCHEMBL16875654 | 0.69 | — | — | |
| SCHEMBL7674679 | 0.68 | — | — | |
| SCHEMBL7473817 | 0.68 | — | — | |
| SCHEMBL12540115 | 0.68 | — | — | |
| SCHEMBL16060705 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116478129-A | Quinoline compound and use thereof | 深圳默元生物科技有限公司 | 2023-07-25 | — | — | CN | claimed |
| CN-118344370-A | Isoindolinone and indazole compounds for EGFR degradation | C4医药公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-114901277-B | Isoindolinone and indazole compounds for EGFR degradation | C4医药公司 | 2024-05-17 | — | — | CN | disclosed |
| US-20240158418-A1 | EGFR Degraders to Treat Cancer Metastasis to the Brain or CNS | C4 THERAPEUTICS, INC. (US) | 2024-05-16 | — | — | US | disclosed |
| EP-4347044-A2 | EGFR DEGRADERS TO TREAT CANCER METASTASIS TO THE BRAIN OR CNS | C4 Therapeutics, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20240076300-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2024-03-07 | — | — | US | disclosed |
| CN-117440813-A | EGFR degrading agents for treating brain or CNS cancer metastasis | C4医药公司 | 2024-01-23 | — | — | CN | disclosed |
| WO-2023138675-A1 | QUINOLINE COMPOUND AND USE THEREOF | 默达药物（香港）有限公司 | 2023-07-27 | — | — | WO | disclosed |
| WO-2023138674-A1 | N-HYDROXYQUINOLINE CARBOXAMIDE COMPOUND AND USE THEREOF | 默达药物（香港）有限公司 | 2023-07-27 | — | — | WO | disclosed |
| CN-116478129-A | Quinoline compound and use thereof | 深圳默元生物科技有限公司 | 2023-07-25 | — | — | CN | disclosed |
| US-8765771-B2 | Condensed pyridine or condensed pyrimidine derivative, and medicinal agent comprising same | KOWA CO., LTD. (JP) | 2014-07-01 | — | — | US | disclosed |
| EP-2586781-A1 | NOVEL CONDENSED PYRIDINE OR CONDENSED PYRIMIDINE DERIVATIVE, AND MEDICINAL AGENT COMPRISING SAME | KOWA CO. LTD. (JP) | 2013-05-01 | — | — | EP | disclosed |
| US-20130102621-A1 | NOVEL CONDENSED PYRIDINE OR CONDENSED PYRIMIDINE DERIVATIVE, AND MEDICINAL AGENT COMPRISING SAME | KOWA CO., LTD. (JP) | 2013-04-25 | — | — | US | disclosed |
| US-20030065189-A1 | Processes for producing 4-substituted benzopyran derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-04-03 | — | — | US | disclosed |
| US-6455708-B1 | SUCH AS 2,2-BIS(FLUOROMETHYL)-N-(2-CYANOETHYL)-6-TRIFLUOROMETHYL-2H-1-BENZOPYRAN-4 -CARBOXAMIDE; USEFUL AS MEDICINES, AGRICHEMICALS AND COSMETICS, AND CHEMICAL INTERMEDIATES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-09-24 | — | — | US | disclosed |
| US-6444616-B1 | HERBICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2002-09-03 | — | — | US | disclosed |
| EP-1120412-A1 | PROCESSES FOR THE PREPARATION OF 4-SUBSTITUTED BENZOPYRAN DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-08-01 | — | — | EP | disclosed |
| US-6130225-A | Substituted p-trifluoromethylphenyluracils | BAYER AKTIENGESELLSCHAFT (DE) | 2000-10-10 | — | — | US | disclosed |
| EP-0923562-A1 | SUBSTITUTED P-TRIFLUOROMETHYLPHENYLURACILS | BAYER AG (DE) | 1999-06-23 | — | — | EP | disclosed |
| WO-1998006706-A1 | SUBSTITUTED P-TRIFLUOROMETHYLPHENYLURACILS | BAYER AKTIENGESELLSCHAFT (DE) | 1998-02-19 | — | — | WO | disclosed |